Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
BillionToOne issued a press release on August 5, 2026 announcing financial results for Q2 2026 (quarter ended June 30, 2026), disclosing total revenue of $109.4 million (64% YoY growth), gross margin of 70%, operating income of $5.5 million, and net income of $8.1 million ($0.15 per diluted share). The company also reiterated full-year 2026 revenue guidance of $450–$465 million. This is a standard quarterly earnings release with material financial metrics that would affect investor assessment of the registrant's performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
Honeywell Aerospace reported Q2 2026 financial results with sales of $4.5 billion (up 5% YoY), net income of $0.3 billion, and adjusted EBIT of $1.0 billion, along with updated full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-08-05
Item 5.02
The company granted equity compensation to three named executives: a $9.0 million Bridge Grant to CEO James Currier, a $4.4 million 2026 LTI Award to CFO Joshua Jepsen, and a $2.55 million 2026 LTI Award to General Counsel John Donofrio, each consisting of 50% nonqualified stock options and 50% restricted stock units under the 2026 Stock Incentive Plan.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-08-05
Item 8.01
The Board authorized a $3.5 billion share repurchase program on July 23, 2026, to return value to shareholders, offset dilution from equity compensation, and manage capital structure.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-05
EX-99.1
This is a press release announcing Xanadu's second quarter 2026 financial results, including revenue of $1.5 million, net loss of $42.1 million, and cash position of $312.8 million as of June 30, 2026. The document explicitly states "Xanadu Announces Second Quarter 2026 Results" and includes consolidated balance sheets, statements of operations, and cash flow data. This is a discrete earnings announcement, not a periodic financial report filing, and would materially affect a reasonable investor's assessment of the company's financial performance and cash runway.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-04
Item 2.02
AMD disclosed Q2 2026 financial results on August 4, 2026, reporting record revenue of $11.5 billion (up 50% year-over-year), net income of $2.3 billion, and diluted EPS of $1.38, along with forward guidance for Q3 2026 revenue of approximately $13 billion.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
ADM issued a press release on August 4, 2026, announcing second quarter 2026 financial results, including net earnings of $908 million, EPS of $1.87, and adjusted EPS of $1.84. The company also raised its full-year 2026 adjusted EPS guidance from $4.15–$4.70 to $5.15–$5.60. This is a standard quarterly earnings disclosure with detailed segment performance and forward guidance, clearly fitting the earnings_release category under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
Bio-Rad announced its second-quarter 2026 financial results on August 4, 2026, disclosing net sales of $651.0 million (flat year-over-year), net income of $371.4 million ($13.85 per diluted share), and operating cash flow of $98.7 million, with detailed segment performance and full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 95%
filed 2026-08-04
Item 2.05
Bio-Rad initiated a strategy-driven restructuring plan on July 31, 2026, involving elimination of positions, consolidation of functions, and facility closures worldwide, with estimated pre-tax charges of $80–$90 million primarily for termination benefits, severance, and healthcare, expected to complete by end of fiscal 2027.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-04
Item 2.02
Caterpillar Inc. issued a press release on August 4, 2026 reporting its second-quarter 2026 financial results, including sales and revenues of $20.5 billion (24% increase), profit per share of $7.77, and adjusted profit per share of $8.17, with segment-by-segment performance details.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-04
Item 2.02
Lumen Technologies issued a press release announcing financial results for the second quarter ended June 30, 2026, including revenues of $2.805 billion, net loss of $(201) million, adjusted EBITDA of $802 million, and full-year 2026 guidance. The earnings presentation was furnished in connection with a teleconference held on August 4, 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-04
Item 5.02
John Hinshaw was appointed to the Board of Directors effective immediately, filling a vacancy on the recommendation of the nominating and corporate governance committee. Mr. Hinshaw was determined to be independent under NYSE rules and was appointed to two Board committees, with a prorated RSU grant of $176,250.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-04
Item 2.02
Cummins issued a press release on August 4, 2026, reporting second-quarter 2026 financial results, including record revenues of $9.5 billion, net income of $932 million ($6.73 diluted EPS), and raised full-year 2026 guidance for both revenue (up 10–13%) and EBITDA (18.0–18.5%). This is a standard quarterly earnings disclosure furnished under Item 2.02, with the press release attached as Exhibit 99.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-04
Item 2.02
Revvity announced Q2 2026 financial results on August 4, 2026, disclosing revenue of $730 million, GAAP EPS of $0.48, and adjusted EPS of $1.41, along with raising full-year pro forma revenue guidance to $2.83–$2.86 billion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-04
Item 8.01
Revvity entered into a definitive agreement on July 31, 2026 to divest its Immunodiagnostics business in China for up to $200 million, subject to adjustments and closing conditions, with expected close by end of 2027. The divestiture represents approximately 6% of 2025 revenue.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
This is a clear earnings release for Q3 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release discloses quarterly financial results including net sales of $4,873M (up 7%), pretax earnings of $916M, diluted EPS of $1.28, and updated full-year 2026 guidance with raised outlook. The company also declared a quarterly dividend. This is a standard quarterly earnings disclosure material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-04
Item 2.02
IFF disclosed second quarter 2026 financial results via press release dated August 4, 2026, reporting consolidated sales of $1.95 billion, income before taxes of $64 million, and adjusted operating EBITDA of $408 million for Q2 2026 on a continuing operations basis, along with full-year 2026 guidance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-04
Item 8.01
IFF entered into a definitive Purchase Agreement on May 29, 2026, to sell its Food Ingredients business to CVC Capital Partners for approximately $3.8 billion in net cash proceeds, with expected close by end of Q2 2027. The company characterizes this as a strategic shift with major effect on IFF's operations and results, with the business classified as discontinued operations.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-08-04
Item 7.01
IFF is furnishing recast unaudited financial information (Exhibit 99.1) to reflect the reclassification of its Food Ingredients and SCL disposal groups as discontinued operations. While the underlying transaction (sale of Food Ingredients to CVC Capital Partners, announced May 29, 2026, expected to close by end of Q2 2027) is a material M&A activity, this Item 7.01 disclosure centers on the financial restatement/recast of historical periods to show the impact of the separation. The filing explicitly states "This Form 8-K and the accompanying Exhibit 99.1 do not restate any previously filed financial statements" but furnishes recast information for investor understanding. This is a financial disclosure supporting a major divestiture rather than the divestiture announcement itself, making it a financial-domain event that does not fit the specific M&A category.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-04
Item 5.02
Joseph C. Bartolacci, President and Chief Executive Officer of Matthews International Corporation, announced his retirement effective at the Retirement Date after 29 years with the company and 20 years as CEO. The Board has initiated a succession process to identify his replacement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
McDonald's Corporation issued an investor release on August 4, 2026 reporting second quarter and six-month financial results ended June 30, 2026, with detailed consolidated financial statements showing revenues of $7.099 billion (Q2 2026) and $13.616 billion (six months), operating income, net income, and diluted earnings per share of $3.32 (Q2) and $6.10 (six months). This is a standard quarterly earnings disclosure filed under Item 2.02 with exhibits 99.1 and 99.2 containing the full investor release and supplemental financial information.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-08-04
Item 5.02
Skye Anderson was appointed as Executive Vice President and President of McDonald's USA, effective August 4, 2026, a senior executive role overseeing nearly 14,000 U.S. restaurants and the Company's largest market segment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-04
Item 5.02
The Board appointed David J. Fallon and Michael C. Lenz as directors effective August 4, 2026, expanding the board from nine to eleven members. Both appointees are independent directors with significant executive experience (CFO roles at major public companies including Vertiv, FedEx, and Hexcel), and the company's CEO and Chairman explicitly noted their strategic value in capital allocation and large-scale operations. This is a clear executive appointment event material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
This is a clear earnings release disclosing Pfizer's second-quarter 2026 financial results, including revenues of $15.0 billion, reported loss per share of $(0.04), and adjusted diluted EPS of $0.77. The filing includes updated full-year 2026 revenue guidance raised by $500 million at the midpoint, along with detailed operational performance metrics and product-level revenue drivers. The press release is furnished as Exhibit 99 and constitutes the primary disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-04
Item 2.02
The filing discloses quarterly and six-month earnings results for the periods ended July 4, 2026 and June 28, 2025, presented in a press release format with net sales, operating income, net earnings, and earnings per share. While the filing also mentions a dividend declaration, the primary disclosure under Item 2.02 is the earnings announcement, which is the material financial result that would affect a reasonable investor's assessment of the registrant's performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
Standard Motor Products issued a press release on August 4, 2026 announcing its financial results for the three and six months ended June 30, 2026. The disclosure includes consolidated net sales of $501.6 million for Q2 2026 (up from $493.9 million in Q2 2025), diluted earnings per share of $1.39 (up from $1.17), and reaffirmed full-year guidance. This is a standard quarterly earnings release disclosing material financial results and operational performance metrics.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
This is a clear earnings release for Q2 2026 ended June 30, 2026, disclosed via press release attached as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition). The filing reports net sales of $25.7 million (up 37.6% YoY), net income of $0.7 million (vs. loss of $2.4 million in Q2 2025), and Adjusted EBITDA of $1.5 million (vs. negative $0.3 million in Q2 2025), along with detailed financial statements and management commentary on operational performance and the Midwest acquisition integration.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
This is a clear earnings release disclosing Sysco's fourth quarter and full fiscal year 2026 financial results, including sales ($84.6 billion for FY2026), gross profit, operating income, net earnings, and diluted EPS ($3.66 for FY2026). The press release is attached as Exhibit 99.1 and includes forward-looking guidance for FY2027 (6%-7% sales growth, 9%-11% adjusted EPS growth). Item 2.02 explicitly covers results of operations and financial condition, and this disclosure is material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
The Company issued a press release on August 4, 2026 announcing second-quarter 2026 results, with sales of $1.26 billion (up 7.5%), diluted EPS of $0.41, and adjusted EPS of $1.83. The filing also includes updated 2026 full-year guidance raising adjusted EPS outlook to $6.05-$6.35. This is a standard quarterly earnings disclosure attached as Exhibit 99.1, typical of Item 2.02 filings.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
This is a straightforward earnings release for the second quarter ended June 27, 2026. The Item 2.02 disclosure presents quarterly and year-to-date financial results including total revenue ($1.28 billion for Q2, up 4.6%), net income ($22.86 million for Q2, down 9.6%), and earnings per share ($0.92 for Q2), along with comparable store sales metrics and a dividend declaration. The news release is attached as Exhibit 99.1 and constitutes a standard quarterly earnings announcement material to investors.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-04
Item 5.02
Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine (a $60+ billion business unit) and Executive Committee member, is retiring effective September 1, 2026. While the filing also discloses Tom Cavanaugh's appointment as her successor, the principal disclosed action centers on Taubert's departure from a senior executive role after 21 years. The appointment is presented as a succession event, making the departure the salient event.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-04
Item 2.02
W.W. Grainger issued a press release on August 4, 2026 announcing second quarter 2026 financial results, including net sales of $5.0 billion (up 10.3%), diluted EPS of $12.01 (up 20.5%), and operating margin of 16.1% (up 120 basis points). The company also increased its full-year 2026 guidance. This is a standard quarterly earnings disclosure under Item 2.02, material to investors assessing the registrant's financial performance and outlook.
View raw filing on EDGAR →
6-K
Periodic Interim
confidence 95%
filed 2026-08-04
This is BP's interim financial report for the six-month period ended 30 June 2026, furnished as a Form 6-K. The document contains consolidated financial statements, MD&A, and financial results for the first half of 2026 compared to the prior-year period. While the CEO commentary discusses strategic priorities and portfolio actions (asset sales), the core filing is a periodic interim financial report, not a discrete earnings release or event announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-04
Item 2.02
This is a clear earnings release disclosing Amgen's unaudited financial results for Q2 2026 (three and six months ended June 30, 2026), including total revenues of $10.1 billion (up 10% YoY), GAAP EPS of $4.37 (up 65%), and non-GAAP EPS of $6.29 (up 4%). The filing explicitly states "On August 4, 2026, the Company issued a press release announcing its unaudited results of operations" and includes detailed product sales performance, operating expense analysis, cash flow metrics, and 2026 guidance. This is a material quarterly earnings disclosure typical of Item 2.02.
View raw filing on EDGAR →
6-K
Periodic Interim
confidence 95%
filed 2026-08-04
This is Novo Nordisk's interim financial report for the first half of 2026 (1 January to 30 June 2026), explicitly labeled as such and containing unaudited condensed consolidated financial statements prepared under IAS 34 'Interim Financial Reporting.' The document presents comprehensive financial results, balance sheet, cash flow, and segment data for the six-month period, along with strategic milestones and outlook guidance. This is a periodic interim report itself, not a discrete earnings-release event, and should be deferred for separate processing as a periodic filing.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-04
Item 2.02
Gartner disclosed its second quarter 2026 financial results on August 4, 2026, reporting revenues of $1.7 billion, net income of $275 million, diluted EPS of $4.14, and adjusted EPS of $4.37, along with updated full-year 2026 guidance via press release and scheduled webcast.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
Light & Wonder disclosed quarterly financial results for Q2 2026 (three and six months ended June 30, 2026) via press release attached as Exhibit 99.1. The disclosure includes consolidated revenue of $828 million (2% YoY growth), net income of $120 million (26% YoY increase), and Consolidated AEBITDA of $383 million (9% growth), along with detailed segment performance and forward guidance. This is a standard earnings release under Item 2.02 that would materially affect investor assessment of the registrant's financial condition and operating performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-04
Item 2.02
Pinnacle West Capital Corp issued a press release on August 4, 2026 disclosing Q2 2026 consolidated net income of $178.6 million ($1.43 per diluted share), compared to $192.6 million ($1.58 per share) in Q2 2025, along with detailed financial statements, operational metrics, and 2026 full-year earnings guidance of $4.55–$4.75 per diluted share.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
This is a clear earnings release disclosing Caterpillar Financial Services Corporation's second-quarter 2026 financial results, including revenues of $991 million (up 10% YoY), profit of $145 million (up 6% YoY), and retail new business volume of $3.92 billion (up 9% YoY). The filing explicitly states the press release is attached as Exhibit 99.1 and incorporated into Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-04
Item 2.02
TrueBlue disclosed its second quarter 2026 financial results on August 4, 2026, reporting revenue of $443 million (up 12% year-over-year), a net loss of $3.4 million, and adjusted EBITDA of $11 million, accompanied by an earnings presentation and investor roadshow materials.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-04
Item 5.02
Heather H. Teilhet, the current Executive Vice President, External Affairs, has informed the company that she will resign from her position effective January 1, 2027, due to her appointment as President/CEO of Georgia Electric Membership Corporation. While the disclosure mentions both her departure and the external appointment, the principal action disclosed to investors is her resignation from the registrant, making this a departure event. The departure of a senior executive is material to investors' assessment of the company.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
EOG Resources issued a press release on August 4, 2026 announcing second quarter 2026 financial and operational results, including net income of $2.724 billion, diluted EPS of $5.15, detailed financial statements, and full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
Callaway Golf Company disclosed its second quarter 2026 financial results via press release on August 4, 2026, including net sales of $612.2 million (+2%), GAAP net income from continuing operations of $75.8 million (+67%), and Adjusted EBITDA of $124.9 million (+36%), along with raised full-year guidance. This is a standard quarterly earnings release disclosure under Item 2.02, furnished as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
FRP Holdings issued a press release on August 4, 2026, announcing financial results for the second quarter ended June 30, 2026, disclosing net loss of $0.3 million ($(0.01) per share) versus prior-year net income of $0.6 million ($0.03 per share), along with detailed segment performance metrics and six-month year-to-date results. This is a standard quarterly earnings release filed under Item 2.02 and furnished as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 68%
filed 2026-08-04
Item 1.01
Granite Construction entered into unwind agreements with financial institutions to terminate capped call transactions associated with its $273.7 million convertible notes due 2028, resulting in material cash settlement and effectively facilitating the redemption and conversion of the existing convertible debt.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
This is a clear earnings release disclosing Arrowhead Pharmaceuticals' fiscal 2026 third quarter financial results for the period ended June 30, 2026. The filing includes consolidated condensed financial information showing revenue of $75.3 million, operating loss of $170.1 million, and net loss of $194.3 million, along with detailed commentary on commercial and R&D progress. The press release is furnished as Exhibit 99.1 and is the primary disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
Gilead Sciences announced its second quarter 2026 financial results on August 4, 2026, disclosing total revenues of $7.8 billion (10% increase YoY), diluted loss per share of $(8.45), and non-GAAP diluted loss per share of $(6.75). The press release filed as Exhibit 99.1 provides comprehensive quarterly financial results including product sales by category, gross margins, operating expenses, and updated full-year 2026 guidance. This is a standard quarterly earnings release material to investors assessing the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
Credit Acceptance Corporation issued a press release on August 4, 2026 announcing consolidated net income of $135.9 million ($12.66 per diluted share) for Q2 2026, along with detailed financial metrics, operational highlights, and forward-looking commentary from the CEO. This is a standard quarterly earnings disclosure filed under Item 2.02 with the earnings release attached as Exhibit 99.1, which is the typical format for earnings releases.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-04
Item 2.02
Kadant Inc. announced its financial results for the fiscal quarter ended July 4, 2026, reporting record revenue of $313 million (23% increase), net income of $32.5 million (24% increase), and adjusted EPS of $3.42 (26% increase), along with updated full-year and Q3 guidance. A webcast and conference call to discuss the results is scheduled for August 5, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-04
Item 2.02
Match Group disclosed Q2 2026 financial results on August 4, 2026, reporting total revenue of $853 million, net income of $171 million (up 36% year-over-year), and Adjusted EBITDA of $331 million (up 14% year-over-year), along with detailed segment performance and forward guidance for Q3 2026.
View raw filing on EDGAR →